Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0EDHJ)

• Drug Name: CC-90011 Drug Info
• Synonyms: UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 2	[1]
Non-hodgkin lymphoma	2B33.5	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 118483201
  CAS Number: CAS 1821307-10-1
  TTD Drug ID: DM0EDHJ

Molecule-Related Drug Atlas

Drug(s) Targeting Lysine-specific histone demethylase 1 (LSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IMG-7289	DML9AVG	Acute myeloid leukaemia	2A60	Phase 2	[2]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[3]
ORY-2001	DMYM0UY	Alzheimer disease	8A20	Phase 2	[4]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[5]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[6]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[7]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[8]
Tarnylcypromine derivative 3	DMKJOMC	N. A.	N. A.	Patented	[8]
Cyclic peptide derivative 1	DM78NOU	N. A.	N. A.	Patented	[8]
IMG-7289	DML9AVG	Acute myeloid leukaemia	2A60	Phase 2	[2]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[3]
ORY-2001	DMYM0UY	Alzheimer disease	8A20	Phase 2	[4]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[2]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[5]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[6]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[7]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[8]
Tarnylcypromine derivative 3	DMKJOMC	N. A.	N. A.	Patented	[8]
Cyclic peptide derivative 1	DM78NOU	N. A.	N. A.	Patented	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysine-specific histone demethylase 1 (LSD)	TTNR0UQ	KDM1A_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02875223) A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
• [4] Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
• [5] A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
• [6] Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
• [7] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [8] LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.